Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials

Purpose To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. Methods A retrospective multidatabase cohort study using CPRD primary care...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2021-04, Vol.30 (4), p.472-481
Hauptverfasser: Requena, Gema, Wolf, Achim, Williams, Rachael, Dedman, Daniel, Quint, Jennifer K., Murray‐Thomas, Tarita, Pimenta, Jeanne M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 481
container_issue 4
container_start_page 472
container_title Pharmacoepidemiology and drug safety
container_volume 30
creator Requena, Gema
Wolf, Achim
Williams, Rachael
Dedman, Daniel
Quint, Jennifer K.
Murray‐Thomas, Tarita
Pimenta, Jeanne M.
description Purpose To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. Methods A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics. Results A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively). Conclusions Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.
doi_str_mv 10.1002/pds.5188
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7986187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2494657226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</originalsourceid><addsrcrecordid>eNp1kdtqFTEUhgdR7EHBJ5CAN72ZmuNM5kaQXatCweLhOmQnK92p2ZMxyXSz73yEvoHv5pOYbWs9gDdZP6w_H__ib5onBB8TjOnzyeZjQaS81-wTPAwtEaK_v9OCtVJ0w15zkPMlxnU38IfNHmOsk5Li_ebbKejslz74skXRoTn78QItgh-90QGdJ22KN4DeQwadzAqd6KLr9jOyVaASkbcwFu-2aNLFV5nRxpcVMqsUKwPFZS5prpArQNMc1nHUaYusr7gMu_8wphiQH6tMoMP3r9ebmIJFJXkd8qPmgasDHt_Ow-bT6auPizft2bvXbxcvz1rDmZStIz1xzvW9FWQQhGptobOag2WOOwEYKDF0oBxr3YFwjALmXPD6UiMEYYfNixvuNC_XYE09JOmgpuTXNa-K2qu_N6NfqYt4pfpBdkT2FXB0C0jxywy5qLXPBkLQI8Q5K8p7xrFkXVetz_6xXsY5jfW86hp4J3pKu99Ak2LOCdxdGILVrnVVW1e71qv16Z_h74y_aq6G9saw8QG2_wWp85MPP4E_AEFQu-I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494657226</pqid></control><display><type>article</type><title>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Requena, Gema ; Wolf, Achim ; Williams, Rachael ; Dedman, Daniel ; Quint, Jennifer K. ; Murray‐Thomas, Tarita ; Pimenta, Jeanne M.</creator><creatorcontrib>Requena, Gema ; Wolf, Achim ; Williams, Rachael ; Dedman, Daniel ; Quint, Jennifer K. ; Murray‐Thomas, Tarita ; Pimenta, Jeanne M.</creatorcontrib><description>Purpose To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. Methods A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics. Results A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively). Conclusions Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.5188</identifier><identifier>PMID: 33368820</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Inc</publisher><subject>Asthma ; Chronic obstructive pulmonary disease ; Clinical medicine ; Clinical trials ; Dyspnea ; electronic health record ; feasibility studies ; general practice ; Lung diseases ; Medical research ; Obstructive lung disease ; Original ; Patients ; Practice research ; Primary care ; primary health care ; real world clinical trials ; Respiration</subject><ispartof>Pharmacoepidemiology and drug safety, 2021-04, Vol.30 (4), p.472-481</ispartof><rights>2020 GSK. published by John Wiley &amp; Sons Ltd.</rights><rights>2020 GSK. Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 GSK. published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</citedby><cites>FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</cites><orcidid>0000-0002-1889-6656 ; 0000-0001-9007-6292</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.5188$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.5188$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33368820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Requena, Gema</creatorcontrib><creatorcontrib>Wolf, Achim</creatorcontrib><creatorcontrib>Williams, Rachael</creatorcontrib><creatorcontrib>Dedman, Daniel</creatorcontrib><creatorcontrib>Quint, Jennifer K.</creatorcontrib><creatorcontrib>Murray‐Thomas, Tarita</creatorcontrib><creatorcontrib>Pimenta, Jeanne M.</creatorcontrib><title>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. Methods A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics. Results A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively). Conclusions Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.</description><subject>Asthma</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Dyspnea</subject><subject>electronic health record</subject><subject>feasibility studies</subject><subject>general practice</subject><subject>Lung diseases</subject><subject>Medical research</subject><subject>Obstructive lung disease</subject><subject>Original</subject><subject>Patients</subject><subject>Practice research</subject><subject>Primary care</subject><subject>primary health care</subject><subject>real world clinical trials</subject><subject>Respiration</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kdtqFTEUhgdR7EHBJ5CAN72ZmuNM5kaQXatCweLhOmQnK92p2ZMxyXSz73yEvoHv5pOYbWs9gDdZP6w_H__ib5onBB8TjOnzyeZjQaS81-wTPAwtEaK_v9OCtVJ0w15zkPMlxnU38IfNHmOsk5Li_ebbKejslz74skXRoTn78QItgh-90QGdJ22KN4DeQwadzAqd6KLr9jOyVaASkbcwFu-2aNLFV5nRxpcVMqsUKwPFZS5prpArQNMc1nHUaYusr7gMu_8wphiQH6tMoMP3r9ebmIJFJXkd8qPmgasDHt_Ow-bT6auPizft2bvXbxcvz1rDmZStIz1xzvW9FWQQhGptobOag2WOOwEYKDF0oBxr3YFwjALmXPD6UiMEYYfNixvuNC_XYE09JOmgpuTXNa-K2qu_N6NfqYt4pfpBdkT2FXB0C0jxywy5qLXPBkLQI8Q5K8p7xrFkXVetz_6xXsY5jfW86hp4J3pKu99Ak2LOCdxdGILVrnVVW1e71qv16Z_h74y_aq6G9saw8QG2_wWp85MPP4E_AEFQu-I</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Requena, Gema</creator><creator>Wolf, Achim</creator><creator>Williams, Rachael</creator><creator>Dedman, Daniel</creator><creator>Quint, Jennifer K.</creator><creator>Murray‐Thomas, Tarita</creator><creator>Pimenta, Jeanne M.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1889-6656</orcidid><orcidid>https://orcid.org/0000-0001-9007-6292</orcidid></search><sort><creationdate>202104</creationdate><title>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</title><author>Requena, Gema ; Wolf, Achim ; Williams, Rachael ; Dedman, Daniel ; Quint, Jennifer K. ; Murray‐Thomas, Tarita ; Pimenta, Jeanne M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Asthma</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Dyspnea</topic><topic>electronic health record</topic><topic>feasibility studies</topic><topic>general practice</topic><topic>Lung diseases</topic><topic>Medical research</topic><topic>Obstructive lung disease</topic><topic>Original</topic><topic>Patients</topic><topic>Practice research</topic><topic>Primary care</topic><topic>primary health care</topic><topic>real world clinical trials</topic><topic>Respiration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Requena, Gema</creatorcontrib><creatorcontrib>Wolf, Achim</creatorcontrib><creatorcontrib>Williams, Rachael</creatorcontrib><creatorcontrib>Dedman, Daniel</creatorcontrib><creatorcontrib>Quint, Jennifer K.</creatorcontrib><creatorcontrib>Murray‐Thomas, Tarita</creatorcontrib><creatorcontrib>Pimenta, Jeanne M.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Requena, Gema</au><au>Wolf, Achim</au><au>Williams, Rachael</au><au>Dedman, Daniel</au><au>Quint, Jennifer K.</au><au>Murray‐Thomas, Tarita</au><au>Pimenta, Jeanne M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2021-04</date><risdate>2021</risdate><volume>30</volume><issue>4</issue><spage>472</spage><epage>481</epage><pages>472-481</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. Methods A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics. Results A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively). Conclusions Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33368820</pmid><doi>10.1002/pds.5188</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1889-6656</orcidid><orcidid>https://orcid.org/0000-0001-9007-6292</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1053-8569
ispartof Pharmacoepidemiology and drug safety, 2021-04, Vol.30 (4), p.472-481
issn 1053-8569
1099-1557
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7986187
source Wiley Online Library Journals Frontfile Complete
subjects Asthma
Chronic obstructive pulmonary disease
Clinical medicine
Clinical trials
Dyspnea
electronic health record
feasibility studies
general practice
Lung diseases
Medical research
Obstructive lung disease
Original
Patients
Practice research
Primary care
primary health care
real world clinical trials
Respiration
title Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T23%3A08%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20using%20Clinical%20Practice%20Research%20Datalink%20data%20to%20identify%20patients%20with%20chronic%20obstructive%20pulmonary%20disease%20to%20enrol%20into%20real%E2%80%90world%20trials&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Requena,%20Gema&rft.date=2021-04&rft.volume=30&rft.issue=4&rft.spage=472&rft.epage=481&rft.pages=472-481&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.5188&rft_dat=%3Cproquest_pubme%3E2494657226%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2494657226&rft_id=info:pmid/33368820&rfr_iscdi=true